Peter A. Thompson - 11 Jun 2026 Form 4 Insider Report for Corvus Pharmaceuticals, Inc. (CRVS)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: CRVS
Reported as of: 11 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Jun 2026, 17:06:45 UTC
Prior SEC filing: 17 Jun 2026
Next SEC filing: 18 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Leiv Lea, as Attorney-in-Fact for Peter A. Thompson

Key filing fact

Peter A. Thompson filed Form 4 for Corvus Pharmaceuticals, Inc. (CRVS) on 15 Jun 2026.

Key facts

This page summarizes Peter A. Thompson's Form 4 filing for Corvus Pharmaceuticals, Inc. (CRVS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Jun 2026, 17:06.

Change

Previous filing in this sequence was filed on 17 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001357522 Primary reporting owner

Thompson Peter A.

Relationship: Director, 10%+ Owner
Address: C/O CORVUS PHARMACEUTICALS, INC., 901 GATEWAY BOULEVARD, THIRD FLOOR, SOUTH SAN FRANCISCO
Signature: /s/ Leiv Lea, as Attorney-in-Fact for Peter A. Thompson
Signature date: 15 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRVS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +15,000
Change %
Price: $0.000000^*
Shares after: 15,000
Date: 11 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $11.60
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.

Footnote F2

Pursuant to an agreement with OrbiMed Advisors LLC ("Advisors") and OrbiMed Capital GP V LLC ("GP V"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.